RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer: Triple-Drug combo tested after immunotherapy fails
Disease control Recruiting nowThis study tests a combination of three drugs (carboplatin, paclitaxel, and cetuximab) in people with advanced head and neck cancer that has returned or spread. Participants must have already tried the immunotherapy drug pembrolizumab (with or without chemotherapy) and it stopped…
Matched conditions: RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Centre Paul Strauss • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a simple test predict immunotherapy success in head and neck cancer?
Knowledge-focused Recruiting nowThis study is collecting blood and tumor samples from 60 people with recurrent or metastatic head and neck cancer who are receiving standard anti-PD1 immunotherapy. The goal is to find biological markers that can predict whether the immunotherapy will work. Researchers will analy…
Matched conditions: RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC